Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how ...
The new report explained that the link between psoriasis and sleep disorders “is likely multifactorial, driven by ...
Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and ...
Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications ...
Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and ...
Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.
At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation. The Academy of Managed Care Pharmacy (AMCP) ...
Ultimate disposition showed 54% approval (7% same-day; 47% after multiple days) and 46% denial, with 27% rejected within 1 ...
Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity ...
Oncology care is constantly evolving, and it’s important for clinicians and pharmacists alike to stay up-to-date on various ...
The Greater Philadelphia Business Coalition on Health will anchor a NACDD-selected 2026 regional summit to expand employer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results